Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 36

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Frequency, clinical presentation, and outcomes of drug-induced liver injury after liver transplantation

Sembera, Stepan, Lammert, Craig, Talwalkar, Jayant A., Sanderson, Schuyler O., Poterucha, John J., Hay, Eileen J., Wiesner, Russell H., Gores, Gregory J., Rosen, Charles B., Heimbach, Julie K., Charlton, Michael R.·2012·Liver Transplantation

Abstract

Drug-induced liver injury (DILI) is increasingly being recognized as a common cause of acute hepatitis. The clinical impact of DILI after liver transplantation (LT) is not known. The aim of this study was to describe the frequency, clinical presentation, and outcomes of DILI in LT recipients. LT recipients with possible DILI were identified with electronic pathology records and clinical note database retrieval tools. Diagnostic criteria were applied to identify cases of DILI. Twenty-nine of 1689 LT recipients (1.7%) were identified with DILI. The mean age was 52 years, and 52% were women. The major indications for LT were primary sclerosing cholangitis (28%), cholangiocarcinoma (14%), and hepatocellular carcinoma (14%). The severity of DILI was mild or moderate in 92% of the cases. Nausea or diarrhea (31%), jaundice (24%), and pruritus (10%) were the most common symptoms at the time of diagnosis. The mean biochemistry values were as follows: alanine aminotransferase, 204 ± 263 U/L; aspartate aminotransferase, 108 ± 237 U/L; alkaline phosphatase, 469 ± 689 U/L; and total bilirubin, 1.9 ± 10.3 mg/dL. The median duration of medication use until the diagnosis of DILI was 57 days, and the major agent classes were antibiotics (48%), immunosuppressive agents (14%), and antihyperlipidemic drugs (7%). Trimethoprim-sulfamethoxazole was the most common implicated agent (n = 11). Serum liver enzymes improved within a median time of 34 days (range = 5–246 days) after drug withdrawal. Hepatic retransplantation or death did not occur. Among the 50 cases with possible DILI explained by other causes, 13 individuals (26%) had no alternative diagnosis despite histological findings compatible with DILI. In conclusion, DILI is a rare yet underrecognized event among LT recipients. The majority of cases are not clinically severe, and they resolve after drug cessation without hepatic retransplantation or death. Liver Transpl, 2012. © 2012 AASLD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/lt.23424

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 22

  1. Watkins, 2006, Druginduced liver injury: summary of a single topic clinical research conference., Hepatology, 43, 618, 10.1002/hep.21095 · DOI · Paper page
  2. Bjornsson, 2010, Review article: druginduced liver injury in clinical practice., Aliment Pharmacol Ther, 32, 3, 10.1111/j.1365-2036.2010.04320.x · DOI · Paper page
  3. Navarro, 2006, Drugrelated hepatotoxicity., N Engl J Med, 354, 731, 10.1056/NEJMra052270 · DOI · Paper page
  4. Fontana, 2010, Standardization of nomenclature and causality assessment in druginduced liver injury: summary of a clinical research workshop., Hepatology, 52, 730, 10.1002/hep.23696 · DOI · Paper page
  5. BenAri, 2003, Intrahepatic cholestasis after liver transplantation., Liver Transpl, 9, 1005, 10.1053/jlts.2003.50212 · doi:10.1053/jlts.2003.50212
  6. Zhenglu, 2007, A clinicalpathological analysis of druginduced hepatic injury after liver transplantation., Transplant Proc, 39, 3287, 10.1016/j.transproceed.2007.08.096 · DOI
  7. Mantel, 2007, Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma., Liver Transpl, 13, 1372, 10.1002/lt.21107 · DOI
  8. Danan, 1993, Causality assessment of adverse reactions to drugsI. A novel method based on the conclusions of international consensus meetings: application to druginduced liver injuries., J Clin Epidemiol, 46, 1323, 10.1016/0895-4356(93)90101-6 · DOI · Paper page
  9. Munoz, 1990, Intrahepatic cholestasis and phospholipidosis associated with the use of trimethoprimsulfamethoxazole., Hepatology, 12, 342, 10.1002/hep.1840120223 · DOI
  10. Carson, 1993, Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines., Ann Intern Med, 119, 576, 10.7326/0003-4819-119-7_Part_1-199310010-00005 · DOI
  11. Yao, 1997, Trimethoprimsulfamethoxazoleinduced vanishing bile duct syndrome., Am J Gastroenterol, 92, 167
  12. Kowdley, 1992, Prolonged cholestasis due to trimethoprim sulfamethoxazole., Gastroenterology, 102, 2148, 10.1016/0016-5085(92)90346-Z · DOI
  13. Sterneck, 1991, Azathioprine hepatotoxicity after liver transplantation., Hepatology, 14, 806, 10.1002/hep.1840140511 · doi:10.1002/hep.1840140511
  14. Gane, 1994, Nodular regenerative hyperplasia of the liver graft after liver transplantation., Hepatology, 20, 88, 10.1002/hep.1840200114 · DOI
  15. Taniai, 2008, Hepatotoxicity caused by both tacrolimus and cyclosporine after living donor liver transplantation., J Nihon Med Sch, 75, 187, 10.1272/jnms.75.187 · doi:10.1272/jnms.75.187
  16. Neff, 2004, Sirolimusassociated hepatotoxicity in liver transplantation., Ann Pharmacother, 38, 1593, 10.1345/aph.1E165 · DOI
  17. Lovell, 2004, Acute hepatic allograft rejection: a comparison of patients with and without centrilobular alterations during first rejection episode., Liver Transpl, 10, 369, 10.1002/lt.20094 · doi:10.1002/lt.20094
  18. Hassoun, 2004, Centrilobular necrosis after orthotopic liver transplantation: association with acute cellular rejection and impact on outcome., Liver Transpl, 10, 480, 10.1002/lt.20122 · doi:10.1002/lt.20122
  19. Khettry, 2002, Centrilobular histopathologic changes in liver transplant biopsies., Hum Pathol, 33, 270, 10.1053/hupa.2002.32225 · doi:10.1053/hupa.2002.32225
  20. Gomez, 1994, Etiopathogenesis and prognosis of centrilobular necrosis in hepatic grafts., J Hepatol, 21, 441, 10.1016/S0168-8278(05)80325-3 · doi:10.1016/s0168-8278(05)80325-3
  21. Watt, 2010, Evolution of causes and risk factors for mortality postliver transplant: results of the NIDDK longterm followup study., Am J Transplant, 10, 1420, 10.1111/j.1600-6143.2010.03126.x · DOI · Paper page
  22. Laish, 2011, Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events., Liver Transpl, 17, 15, 10.1002/lt.22198 · DOI · Paper page

Cited by

See all 36

Metadata

Authors
Sembera, S., Lammert, C., Talwalkar, J. A., Sanderson, S. O., Poterucha, J. J., Hay, E. J., Wiesner, R. H., Gores, G. J., Rosen, C. B., Heimbach, J. K., & Charlton, M. R.
Venue
Liver Transplantation
Published
2012-07
Volume
18
Issue
7
Pages
803-810
ISSN
1527-6465
Cited by
36
References
1
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.